A landmark antimicrobial resistance (AMR) study by the Ineos Oxford Institute has demonstrated a potential breakthrough in combating Nigeria’s high infant mortality rates, with findings particularly relevant for Rivers State’s healthcare challenges. The research, conducted in hospitals across Nigeria, revealed that improved diagnostics and targeted antibiotic use could reduce newborn sepsis deaths by nearly 50%.
The study found that conventional first-line antibiotics frequently fail against resistant infections, but introducing affordable blood culture diagnostics enabled precise treatment. “We discovered common antibiotics were often ineffective against neonatal sepsis,” explained Dr. Kenneth Iregbu, the Nigerian co-lead researcher. “Accurate diagnostics allowed life-saving treatment adjustments.”
For Port Harcourt’s struggling neonatal units, the research highlights critical needs: reliable diagnostic tools to replace guesswork prescriptions, and sustained training for medical staff. The project’s laboratory upgrades and hands-on training components proved vital to its success.
Related News: WHO Calls for Urgent Action on Hepatitis and Liver Cancer
However, researchers warn of sustainability challenges. “Temporary interventions collapse without continued investment,” cautioned Dr. Kirsty Sands, IOI Scientific Lead. The institute is now piloting solar-powered labs in seven hospitals to create more resilient systems.
Rivers State health officials are reviewing the findings as they work to improve infant survival rates. The study provides a clear roadmap: invest in diagnostics, build local capacity, and prioritize antimicrobial stewardship to protect vulnerable newborns.
The research comes as Nigeria battles one of the world’s highest newborn mortality rates, with sepsis accounting for nearly a quarter of infant deaths. Port Harcourt’s maternal health facilities could significantly benefit from adopting the study’s evidence-based approach.
